

**IN SILICO EXPLORATION OF PHOSPHOLIPASE A<sub>2</sub> INHIBITOR COMPOUNDS FROM *Lufariella variabilis* AS ANTIVENOM OF *Ophiophagus hannah*****EKSPLORASI SENYAWA INHIBITOR FOSFOLIPASE A<sub>2</sub> DARI *Lufariella variabilis* SEBAGAI ANTIVENOM *Ophiophagus hannah* SECARA IN SILICO**Romario Dion<sup>1)</sup>, Muhammad F Ewaldo<sup>2\*)</sup>, Muhammad F Fauzaan<sup>2)</sup>, Ilham A Wand<sup>1)</sup>, Rina S Asih<sup>1)</sup>

Received : October, 29 2021

Accepted : February, 7 2022

**Authors affiliation:**<sup>1)</sup>Biotechnology Study Program, Department of Biology, Faculty of Science and Mathematics, Diponegoro University, Indonesia<sup>2)</sup>Biology Study Program, Department of Biology, Faculty of Science and Mathematics, Diponegoro University, Indonesia**Correspondence email:**

\*muhammadfarrelewaldo@gmail.com

**How to cite:**Dion R, MF Ewaldo, MF Fauzaan, IA Wand<sup>1)</sup>, RS Asih. 2022. In silico exploration of phospholipase A<sub>2</sub> inhibitor compounds from *Lufariella variabilis* as antivenom of *Ophiophagus hannah*. *Journal of Tropical Biology* 10 (1): 47-54.**ABSTRACT**

The King Cobra (*Ophiophagus hannah*) is a venomous snake found in Southeast Asia and South Asia. Globally, it is estimated that there are 81,000 to 138,000 cases of snakebite deaths from 1.8 million to 2 million snakebite cases. The limited availability of antivenom is a problem in handling snake venom poisoning. Exploration of natural ingredients is needed as a preventive measurement from the spread of toxins when they are inside the body. Exploration could be carried out by utilizing natural metabolite compounds that can be inhibitors of the phospholipase A<sub>2</sub> (PLA<sub>2</sub>) enzyme. *Lufariella variabilis* is known as a marine organism that can produce sesterterpenoid compounds and has the potential as an inhibitor of the phospholipase A<sub>2</sub> enzyme. This study aims to explore the potential of sesterterpenoid compounds produced by *Lufariella variabilis* as an in silico inhibitor of phospholipase A<sub>2</sub>. Several methods used in this research are molecular docking simulation, toxicity test using pkCSM and Toxtree, and chemical bond analysis using Discovery Studio. The results showed that the manoalide compound was the most potent compound of the other sesterterpenoid compounds in its ability to become a snake antivenom candidate.

Keywords: King Cobra, *Lufariella variabilis*, Phospholipase A<sub>2</sub>**ABSTRAK**

King Cobra (*Ophiophagus hannah*) merupakan salah satu ular berbisa yang ditemukan di Asia Tenggara dan Asia Selatan. Kasus kematian akibat gigitan ular secara global diestimasikan sekitar 81.000 hingga 138.000 kasus dari 1,8 juta hingga 2 juta kasus gigitan ular. Ketersediaan antivenom yang terbatas menjadi permasalahan penanganan dalam keracunan bisa ular. Eksplorasi bahan alam diperlukan sebagai tindakan preventif dari menyebarnya racun ketika berada dalam tubuh. Eksplorasi dapat dilakukan dengan memanfaatkan senyawa metabolit alami yang dapat menjadi inhibitor terhadap enzim fosfolipase A<sub>2</sub> (PLA<sub>2</sub>). *Lufariella variabilis* diketahui sebagai organisme laut yang memiliki kemampuan menghasilkan senyawa golongan sesterterpenoid serta berpotensi sebagai inhibitor enzim fosfolipase A<sub>2</sub>. Penelitian ini bertujuan untuk mengeksplorasi potensi senyawa sesterterpenoid yang dihasilkan oleh *Lufariella variabilis* sebagai inhibitor fosfolipase A<sub>2</sub> secara in silico. Beberapa metode yang dilakukan dalam penelitian ini adalah simulasi penambatan molekuler (molecular docking), uji toksisitas dengan pkCSM dan Toxtree serta analisis ikatan kimia menggunakan Discovery Studio. Hasil penelitian menunjukkan senyawa manoalide adalah senyawa yang paling potensial dari pada senyawa sesterterpenoid lainnya dalam kemampuannya menjadi kandidat antivenom ular.

Kata kunci: fosfolipase A<sub>2</sub>, King Cobra, *Lufariella variabilis***INTRODUCTION**

Snakes are reptiles whose existence is feared by humans. Many species of snakes are known to be able to attack humans with venomous bites that have the potential to cause some damage, such as bleeding, impaired kidney function, and local tissue damage [1]. Global snakebite deaths are estimated to be around 81,000 to 138,000 cases, from 1.8 to 2 million snakebite cases [2]. In Indonesia, snakebite cases were estimated in 2007 as many as 12,739 – 214,883 cases with 2000 – 11,581 deaths [3]. Snakebite sufferers experience high morbidity and mortality due to inadequate

access to health services and a low supply of antivenom, which is the only specific therapy [4]. In addition, the price of antivenom is very expensive, so that ordinary people tend to underestimate the case of snake bites and choose to use local medicines that have not been proven to be effective in healing snake bites. One of the snakes that have a venomous bite is the King Cobra (*Ophiophagus hannah*). King Cobra is known as a species of snake that spreads in South Asia and Southeast Asia [5].

King Cobra venom has been studied since the early 1970s. Various components identified in the snake venom are L-amino acid oxidase enzymes,

metalloproteinases, Three Finger Toxins (3FTxs), and phospholipase A<sub>2</sub> (PLA<sub>2</sub>) [6]. A study of the genome of the King Cobra from Indonesia (Bali Specimen) indicated the presence of phospholipase A<sub>2</sub> in the snake's venom [7].

PLA<sub>2</sub> enzyme is a multi-toxic enzyme that systematically induces various pathophysiological changes in snakebite sufferers. PLA<sub>2</sub> with Asp49 amino acid on the active site will work in hydrolyzing ester bonds in phospholipids found in plasma membranes of various cells, including erythrocytes, to induce plasma membrane lesions and hemolysis [8]. In addition, these compounds can damage mitochondria, erythrocytes, leukocytes, platelets, peripheral nerves, striated muscles, endothelium of blood vessels, and cause the release of histamine and anticoagulants [9].

Phospholipase A<sub>2</sub> (PLA<sub>2</sub>) enzyme isolated from snake venom showed inflammatory symptoms such as acute pain, edema, hypotension, bleeding until the termination of Neuromuscular Junction (NMJ) blockade [10]. The PLA<sub>2</sub> enzyme has the potential to be an inhibitory target that can be used in exploring metabolites found in nature that have potential as antivenom. The content of PLA<sub>2</sub> in snake venom can be neutralized with natural inhibitors derived from marine organisms, which are antivenom reservoirs. One of the marine organisms that have the potential to produce snake venom neutralizing compounds is *Luffariella variabilis*.

*Luffariella variabilis* is a species of marine sponge that produces metabolites that have the potential as antivenom. In addition, this sponge contains compounds that have anti-inflammatory properties. Several sesterterpenoid compounds were found in *L. variabilis*, including manoalide, secomanoalide, luffariellolide, luffariellin A and B and luffolide [11]. A study showed that manoalide isolated from *L. variabilis* could inhibit the extracellular PLA<sub>2</sub> activity of cobras and rattlesnakes with IC<sub>50</sub> values of 1.9 and 0.7 M, respectively [10].

An in silico exploration approach using the software can be an effective approach as an initial preparation before the in vivo testing phase in the laboratory. In addition, the use of the in silico method can minimize the risks that will occur when testing in the laboratory.

Exploration of compounds from these sponges is a major concern for researchers in realizing the use and conservation of marine sponge diversity in Indonesia. Therefore, this study aims to explore potential compounds from *Luffariella variabilis* which can be inhibitors of the PLA<sub>2</sub> enzyme in silico.

## METHODS

**Preparation of phospholipase A<sub>2</sub> enzyme 3D structure.** Acidic Phospholipase A<sub>2</sub> from the venom of *Ophiophagus hannah* (code 1GP7) was downloaded from *RCSB Protein Data Bank* ([www.rcsb.org](http://www.rcsb.org)) in pdb format. The 3D structure was opened by using *PyMol*. Water molecule as residue in the enzyme was removed and also saved in pdb format.

**Ligand preparation.** The compounds produced by *Luffariella variabilis* were used as ligands in inhibiting the action of the phospholipase A<sub>2</sub> enzyme. Ligands, which were metabolites produced by these species, were available on the PubChem website ([www.pubchem.ncbi.nlm.nih.gov](http://www.pubchem.ncbi.nlm.nih.gov)). The structure of the ligands was downloaded in sdf format. Some of the ligands downloaded on the Pubchem website were Luffariellolide (5387248), Luffolide (3081204), Luffariellin A (6091135), Luffariellin B (6391100), Manoalide (5942250), Secomanoalide (5387263). The selection of the sesterterpenoid compounds from *L. variabilis* was based on data obtained from Folmer [10]. In addition, the native ligand used as a comparison is Vitamin E (14985) [12]. Vitamin E had known as an effective inhibitor for the PLA<sub>2</sub> enzyme [13]. Each compounds further information could be seen in Table 1. The ligands were opened using the *PyMol* software and saved in pdb format.

**Molecular docking simulation.** Molecular docking simulations were performed using *PyRx*. The simulation aimed to determine affinity energy between a ligand and a protein, showing the strength of the bond between the two molecules through a calculation. The selected tab in *PyRx* is Vina Wizard. The simulation was begun by adding a macromolecule in the form of a protein pdb file for the phospholipase A<sub>2</sub> enzyme. The simulation was continued by adding ligands in pdb format. The macromolecule and one of the ligands were blocked, then the forward button was clicked. After that, the entire surface of the protein was tested by selecting maximize. The forward button was clicked again. The docking process ran until it brought up an affinity energy number from the docking simulation between the protein and the ligand. The docking simulation was repeated for the next ligands. All docking simulation results between all ligands and proteins in the form of affinity values are arranged in tabular form.

**Molecular docking result analysis.** All molecular docking simulation results between all ligands and proteins in the form of affinity values were arranged in tabular form. The analysis was carried out by determining the ligand that had the most negative affinity value. The most negative affinity value indicated the strongest ligand that

**Table 1.** Ligand name from *Lufariella variabilis* based on PubChem website

Compound Name	IUPAC Name	Compound ID
<b>Manoalide</b>	2-hydroxy-3-[6-hydroxy-5-[(E)-4-methyl-6-(2,6,6-trimethylcyclohexen-1-yl)hex-3-enyl]-3,6-dihydro-2H-pyran-2-yl]-2H-furan-5-one	5942250
<b>Secomanoalide</b>	(E,2E)-2-[3-hydroxy-3-(2-hydroxy-5-oxo-2H-furan-3-yl)propylidene]-6-methyl-8-(2,6,6-trimethylcyclohexen-1-yl)oct-5-enal	5387263
<b>Luffariellolide</b>	3-[(3E,7E)-4,8-dimethyl-10-(2,6,6-trimethylcyclohexen-1-yl)deca-3,7-dienyl]-2-hydroxy-2H-furan-5-one	5387248
<b>Luffariellin A</b>	2-hydroxy-3-[6-hydroxy-5-[(E)-4-methyl-6-(2-methyl-1-prop-1-en-2-ylcyclopentyl)hex-3-enyl]-3,6-dihydro-2H-pyran-2-yl]-2H-furan-5-one	6091135
<b>Luffariellin B</b>	(E,2Z)-2-[3-hydroxy-3-(2-hydroxy-5-oxo-2H-furan-3-yl)propylidene]-6-methyl-8-(2-methyl-1-prop-1-en-2-ylcyclopentyl)oct-5-enal	6391100
<b>Luffolide</b>	[(1R)-2-[(1R,2S,4aS,4bS,8aS,10aS)-2-formyl-4b,8,8,10a-tetramethyl-2,3,4,4a,5,6,7,8a,9,10-decahydro-1H-phenanthren-1-yl]-1-[(2R)-2-hydroxy-5-oxo-2H-furan-3-yl]ethyl] acetate	3081204
<b>Vitamin E</b>	(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol	14985

bonds with the protein. The binding affinity between ligand and protein was referred to as Gibbs Free Energy ( $\Delta G$ ) [14]. Gibbs free energy was the amount of energy used to carry out the chemical reaction. The bond interaction between protein and ligand was stable if the Gibbs free energy value ( $\Delta G$ ) was negative [15].

**Enzyme and ligand complex visualization.** Visualization of the interaction between the ligand and the enzyme after the enzyme-ligand complex was performed using *PyMol* software for visualization in three-dimensional (3D) and software for visualization in two-dimensional (2D) using *BIOVIA Discovery Studio*. This interaction analysis aimed to understand the structure and binding of ligands to proteins.

**Pharmacology characteristics prediction.** Prediction of pharmacological properties was carried out to determine the bioavailability of a compound to become a drug. Pharmacological prediction used Lipinski's five rules. Analysis of pharmacological properties was carried out using *SCFBio* (<http://www.scfbio-iitd.res.in/>). The analysis began by entering the pdb file of a ligand then clicking the submit button. The results of the analysis of the pharmacological properties of several ligands were arranged in tabular form.

**Toxicity test.** Toxicity tests were carried out by using Toxtree and pkCSM ([www.biosig.unimelb.edu.au/pkcsm/prediction](http://www.biosig.unimelb.edu.au/pkcsm/prediction)).

## RESULTS AND DISCUSSION

**Results of binding affinity values from various ligands to PLA<sub>2</sub> enzyme after molecular docking simulation.** Molecular docking simulation was a method used to determine the conformation of the interaction of the test compound on the active site of the target protein receptors and which test compound had the best

affinity values for the target protein receptor [16]. The best ligand parameter obtained after molecular docking simulation is shown by the binding affinity results. According to Muttaqin [16], binding affinity was an important aspect that must be considered in the interaction between ligands and receptors. A lower binding affinity value indicated that a compound required less energy to bind or interact with the receptor. In other words, a lower binding affinity value had a greater potential to interact with the target protein [17]. The PLA<sub>2</sub> enzyme produced by the King Cobra snake is classified as Secreted PLA<sub>2</sub> Enzymes. Secreted PLA<sub>2</sub> had the characteristics of low molecular weight, had six disulfides bonds, required histidine on the active site, and required Ca<sup>2+</sup> as a cofactor [18]. Thus, the enzyme used was classified as a holoenzyme.

The results were obtained from the binding affinity value of molecular docking simulation using PyRx with phospholipase A<sub>2</sub> enzyme as a macromolecule and metabolites that came from of Five. There were five things in Lipinski's rule, namely, the molecular weight was less than 500 Da, the LogP value was less than 5, the donor hydrogen bond was less than 5. The acceptor hydrogen bond was less than 10, and the molar refractivity was between 40-130 [21, 22]. The binding affinity value used was at RMSD 0.0 Å. Susanti and colleagues stated that the molecular docking method was valid if it had an RMSD value  $\leq 3$  Å [19].

Based on Table 2, Manoalide had the lowest binding affinity value of -9.2, followed by Secomanoalide with a binding affinity value of -8.9. It could be concluded that Manoalide is the most potent compound as an inhibitor of the phospholipase A<sub>2</sub> enzyme by binding affinity test. This was consistent with a study conducted by

**Table 2.** Binding affinity value from various ligand compounds to PLA<sub>2</sub>

Ligand	Binding Affinity	RMSD/ub	RMSD/lb
Luffariellin A	-8.8	0	0
Luffariellin B	-8	0	0
Manoalide	-9.2	0	0
Secomanoalide	-8.9	0	0
Luffariellolide	-8.7	0	0
Luffolide	-8.7	0	0
Vitamin E ( <i>Native</i> )	-8.2	0	0

Yarla and colleagues in which phospholipase A<sub>2</sub> (PLA<sub>2</sub>) was a group of enzymes that break down phospholipids specifically at the sn-2 position to release free fatty acids, mostly arachidonic acid (AA) and lysophospholipids (LPL). PLA<sub>2</sub> inhibition prevented the release of AA and LPL. Therefore, the researchers had considered that PLA<sub>2</sub> could be a better therapeutic target than the downstream enzymes of cyclooxygenase and lipoxygenase [20]. The study also attached a table of various compounds capable of being inhibitors of the PLA<sub>2</sub> group, one of them was Manoalide that came from *Luffariella variabilis*. The second-order after Manoalide was Luffariellin A, which has a binding affinity value of -8.8, followed by Luffariellolide and Luffolide with a binding affinity value of -8.7.

**Pharmacological test results.** The search for drug candidates was carried out by in silico drug feasibility testing using the "Lipinski Rule of Five" principle. Planning an oral drug follows Lipinski's rules. The molecular weight of a compound was related to the permeability of a drug in the body. The increase in molecular weight could be correlated with a decrease in the permeability of a compound in the digestive and central nervous systems. The decrease in the rate of permeability of a compound to the lipid bilayer could also be associated with an increase in the molecular weight of a compound so that compounds with higher molecular weights tend to be orally inactive compared to compounds with lower molecular weights [23].

Log P was expressed as the logarithm of the ratio of the drug that was divided into the organic phase with that in the aqueous phase or commonly referred to as lipophilicity. Lipophilicity was described as the ability of a molecule to partition

with octanol or water. Lipophilicity was a chemical property that was generally considered to be very relevant to the absorption rate [24]. As many as 90% of compounds showing a Log P value of less than 5 had bioavailability for oral consumption [23].

The hydrogen bonding of donors that was more than the standard set by Lipinski's rule can reduce the ability of a molecule to penetrate the multiple membrane layers (membrane bilayer). A particular compound that exhibits a large number of donor hydrogen bonds tended to partition with a solvent with strong hydrogen bonds such as water rather than the lipophilic environment generally found in cell membranes. A large number of acceptor hydrogen bonds could also reduce the ability of a molecule to penetrate the lipophilic environment because it tends to interact with water [23]. Lipinski and other researchers [25] found that adding up the nitrogen and oxygen atoms in a molecule can provide a good representation of the correlation to the bioavailability of these compounds as drug candidates.

Based on Lipinski's rule of the five compounds (Table 3), only Secomanoalide did not meet the qualifying standard. Secomanoalide had a molecular mass, hydrogen bond donor, and acceptor that exceeded the limit. The same applies to the level of high lipophilicity, and molar refractivity exceeded the limit as well. Manoalide, which was based on the value of binding affinity as the most potent compound, had met the requirements of the five Lipinski rules for drug candidates. Likewise with Luffariellin A was the second most potent candidate compound as the same antivenom. The Lipinski rule was used as a consideration of whether the drug candidate can be used orally or not.

**Table 3.** Pharmacological tests of compounds based on Lipinski's Rule

Ligand	Molecular Weight	H Donor	H Acceptor	Lipophilicity	Molar Refractivity
Luffariellin A	416	2	5	4.710900	116.248566
Luffariellin B	416	2	5	4.553499	117.439568
Luffariellolide	386	1	3	5.686361	124.420761
Luffolide	460	1	6	4.583799	122.690758
Manoalide	416	2	5	4.855000	116.318558
Secomanoalide	1448	12	24	7.247049	343.823456
Vitamin E ( <i>native</i> )	430	1	2	8.840264	134.390778



Drug molecules that did not comply with Lipinski's regulations were not recommended for use orally but were recommended for injection, and zopolrestat was a commercial drug used as a comparison ligand was a drug that was not used orally [26].

**Toxicological analysis of compounds of *Luffariella variabilis*.** Based on Table 4, the results showed that manoalide, which was the best compound in the previous test, had carcinogenicity values of 8 and 9, which means its chemical ability was negative to cause mutations in harmful genes. Based on ISS for in vitro test against *Salmonella typhimurium* bacteria, Manoalide compound had a value of 2 in Table 4, which means that there was no indication of mutagenicity of *S. typhimurium* bacteria. To test the corrosive/irritating properties of the skin, all compounds were safe because they had point 1, which was non-corrosive to the skin. Even in vivo studies with the micronucleus in rodents such as mice/guinea pigs also showed the number 1, which means at least there was a positive warning for the micronucleus assay.

According to Barbezán et al. [27], the mutagenicity test of a compound administered to the bacterium *S. typhimurium* was based on the knowledge that mutagenic substances in bacteria might subsequently be carcinogenic in laboratory animal tests and present a cancer risk to humans.

Based on the test with pkCSM (Table 5) for Manoalide and Luffarielline A compounds, both had their respective advantages and disadvantages. For the AMES test, Manoalide was positive but Luffarielline A was negative. The AMES test played an important role in drug safety. As

explained by Kesuma et al. [28], determining the toxicity of compounds could be done with the AMES Toxicity test. AMES Toxicity Test was a widely used method to assess the mutagenic potential of compounds using bacteria. A positive test result indicated that the compound was mutagenic and therefore could act as a carcinogen.

It was different with the hepatotoxicity test, where Manoalide had a negative result while Luffarielline A had a positive result. If there were toxic compounds in liver cells, there would be a change in the permeability of the cell membrane. So that the enzymes that should be in the cell finally came out of the cell and were in the blood [29].

The two potential compound candidates as antivenom did not meet the required criteria. However, the Luffolide compound had the same binding affinity value as Luffariellolide, which was -8.7. In Luffolide, the AMES Toxicity and Hepatotoxicity Test on pkCSM was negative. So, this compound was more potential to be used as a drug candidate compound than Manoalide and Luffarielline A when viewed from the results of pkCSM. Based on the exploration of candidate antivenom compounds, both Luffarielline A and Manoalide had advantages and disadvantages. Likewise, Luffolide even though in the AMES test, hepatotoxicity and the response to allergies was negative/none, but in terms of the maximum dose in the human body based on the test with pkCSM, the number showed below 0 or negative, namely -0.25 as well as in Luffarielline A the result was -1.01.

**Table 4.** Toxicity test by Toxtree

<i>Decision Tree</i>	<b>Luffarielin A</b>	<b>Luffarielin B</b>	<b>Luffariellolide</b>	<b>Manoalide</b>	<b>Secomanoalide</b>
Carcinogenicity & Mutagenicity based on ISS	8,9	1,4,9	8,9	8,9	1,3,9
AMES Test	2	1,4	2	2	1,4
Skin irritation/skin corrosion	1	1	1	1	1
Micronucleus assay	1	1	1	1	1


**Table 5.** Toxicological test by pkCSM

<b>Parameters</b>	<b>Manoalide</b>	<b>Luffarielin A</b>	<b>Luffolide</b>
AMES Toxicity	Yes	No	No
Maximum dose (Human)	0,878	-1,01	-0,25
h ERG I Inhibitor	No	No	No
h ERG II Inhibitor	No	No	No
LD50	2,482	2,222	2,515
LOAEL	0,172	1,896	0,092
Hepatotoxicity	No	Yes	No
Skin Sensitivity	No	No	No
Toxic to <i>T. pyriformis</i>	0,285	0,33	0,312
Minnow Toxicity	3,707	-0,135	-1,617


**Visualization of the interaction between ligands and PLA<sub>2</sub>.** Interaction visualization was done by looking at the binding site representing the location of amino acid residues in forming various interactions with ligands [30] (Figure 1). Manoalide had a bond length of 0.356 nm with the carbon-hydrogen bond with CYS29. Luffarielline A had a bond length of 0.258 nm with the type of bond being donor-donor with GLY30, and for Luffolide itself, it had a bond length of 0.196 nm, with the type of bond being conventional hydrogen bond with ASP49 (Figure 1 and 2). Based on length bond visualization, the most potential result as an antivenom candidate was Luffolide which had the shortest bond distance. The shorter the bond

distance indicated that the intermolecular bonds were getting stronger. As explained by Kilo [31] that because the distance between the ions of a small radius was shorter, the electrostatic attraction between the ions was stronger.

Based on these results, the most potent antivenom compound was considered and selected were Manoalide and Luffolide. Manoalide was selected with the highest consideration in terms of binding affinity value, passing the Lipinski and Toxtree rules criteria. But, the effect of the AMES test on testing with pkCSM was considered a side effect and was also dosed in the safest dose. When viewed from the results of 2D analysis, Luffolide itself had the shortest length bond with the PLA<sub>2</sub>.



**Figure 1.** 2D Visualization of Interaction between PLA<sub>2</sub> with Several Ligand (a) Manoalide (b) Luffarielline A (c) Luffolide (d) Vitamin E. The yellow residue indicated the location of interaction between ligand with the PLA<sub>2</sub>



**Figure 2.** Bond length interaction between PLA<sub>2</sub> with several ligand (a) Manoalide (b) Luffariellin A (c) Luffolide. The yellow residue indicated the location of interaction between ligand with the PLA<sub>2</sub>

## CONCLUSION

Based on the results of molecular docking, Lipinski's five rules, 2D molecular interaction test, and toxicity test, it was found that Manoalide was the most potent compound to be used as an antivenom against cobra (*Ophiophagus hannah*) because it had the highest binding affinity value, passed the five Lipinski rules test, passed the test Toxtree toxicity. However, the Manoalide compound in the pkCSM toxicity test got a positive result against the AMES test, so it was considered ineligible and had the longest bond with the PLA<sub>2</sub>.

## ACKNOWLEDGMENT

Acknowledgments to the lecturers of the Department of Biology at Diponegoro University who have helped during this research process.

## REFERENCES

- [1] Wintoko R, Prameswari NP (2020) Manajemen Gigitan Ular. JK Unila 1(4): 45-52.
- [2] Gutiérrez JM, Calvete JJ, Habib AG, Harrison RA, Williams DJ, Warrell DA (2017) Snakebite envenoming. Nat Rev Dis Primers. 3(17063): 1-20.
- [3] Kasturiratne A, Wickremasinghe AR, Silva N (2008) The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med 5(11): e218.
- [4] Medikanto AR, Silalahi LMMV, Sutarni S (2017) Viperidae snake bite: Kasus Serial. Berkala Ilmiah Kedokteran Duta Wacana 2(2): 361-374.
- [5] Devkota K, Maharjan B, Mandal DN, Giri R, Goode M (2021). Save the King: Human-King Cobra, *Ophiophagus hannah* (Cantor 1836), conflicts and the need for conservation strategies in Nepal. Reptiles & Amphibians 28(2): 197-204.
- [6] Tan CH, Tan KY, Fung SY, Tan NH (2015) Venom-gland transcriptome and venom proteome of the Malaysian King Cobra (*Ophiophagus hannah*). BMC Genomics 16(1): 1-21.
- [7] Vonk FJ, Casewell NR, Henkel CV, Heimberg AM, Jansen HJ, McCleary RJ, Kerkkamp HM, Vos RA, Guerreiro I, Calvete JJ, Wüster W, Woods AE, Logan JM, Harrison RA, Castoe TA, de Koning AP, Pollock DD, Yandell M, Calderon D, Renjifo C, Currier RB, Salgado D, Pla D, Sanz L, Hyder AS, Ribeiro JM, Arntzen JW, van den Thillart GE, Boetzer M, Pirovano W, Dirks RP, Spaik HP, Duboule D, McGlinn E, Kini RM, Richardson MK (2013) The King Cobra genome reveals dynamic gene evolution and adaptation in the snake venom system. Proceedings of the National Academy of Sciences 110(51): 20651-20656.
- [8] Urs NA, Yariswamy M, Joshi V, Nataraju A, Gowda TV, Vishwanath BS (2014) Implications of phytochemicals in snakebite management: present status and future prospective. Toxin Reviews 33(3): 60-83.

- [9] Sutantoyo FF, Gunawan EJ (2016) Antikolinesterase untuk gigitan ular dengan bisa neurotoksik. *Cermin Dunia Kedokteran* 43(1): 14-18.
- [10] Folmer F, Jaspars M, Schumacher M, Dicato M, Diederich M (2010) Marine natural products targeting phospholipases A2. *Biochemical pharmacology* 80(12): 1793-1800.
- [11] Hanani E., Mun'im A, Sekarini R (2005) Identifikasi senyawa antioksidan dalam spons *Callyspongia* sp. dari Kepulauan Seribu. *Majalah Ilmu Kefarmasian* 3(2): 127-133.
- [12] Delmondes PH, Stefani R (2018) Molecular docking studies of natural phenolic compound and derivatives with phospholipase A2. *Orbital: The Electronic Journal of Chemistry* 10(6): 467-74.
- [13] Takeda AAS, Dos Santos JI, Marcussi S, Silveira LB, Soares AM, Fontes MRM (2004) Crystallization and preliminary X-ray diffraction analysis of an acidic phospholipase A<sub>2</sub> complexed with p-bromophenacyl bromide and  $\alpha$ -tocopherol inhibitors at 1.9 and 1.45 Å resolution. *Biochim Biophys Acta* 1699: 281-284.
- [14] Mathur N, Goswami G, Pathak AN (2016) Structural comparison, docking and substrate interaction study of modeled endo-1, 4-beta xylanase enzyme of *Bacillus brevis*. *Journal of Molecular Graphics and Modelling* 74: 337-343.
- [15] Marks DB, Marks AD, Smith CM (2000) *Basic Medical Biochemistry: A Clinical Approach*. Jakarta, Erlangga.
- [16] Muttaqin FZ (2019) Molecular docking and molecular dynamic studies of stilbene derivative compounds as sirtuin-3 (Sirt3) histone deacetylase inhibitor on melanoma skin cancer and their toxicities prediction. *Journal of Pharmacopolium* 2(2).
- [17] Pangastuti A, Amin M, Indriwati SE (2016) Mengungkap potensi senyawa alami melalui teknik Reverse Docking. *Prosiding Seminar Nasional II, Malang, Universitas Muhammadiyah Malang*, 668 – 674.
- [18] Burke JE and Dennis EA (2009) Phospholipase A2 biochemistry. *Cardiovascular drugs and therapy* 23(1): 49-59.
- [19] Susanti NMP, Laksmiani NPL, Dewi PPP, Dewi PYC (2019) Molecular docking terpinen-4-ol pada protein IKK sebagai antiinflamasi pada aterosklerosis secara in silico. *Jurnal Farmasi Udayana* 1(8): 44-49.
- [20] Yarla NS, Bishayee A, Vadhakonda L, Chintala R, Duddukuri GR, Reddanna P, Dowluru SVGK (2016) Phospholipase A2 isoforms as novel targets for prevention and treatment of inflammatory and oncologic diseases. *Current Drug Targets* 17(16): 1940-1962.
- [21] Adriani A (2018) Prediksi senyawa bioaktif dari tanaman Sanrego (*Lunasia amara* Blanco) sebagai inhibitor enzim siklooksigenase-2 (Cox-2) melalui pendekatan *molecular docking*. *Jurnal Ilmiah Pena: Sains dan Ilmu Pendidikan* 10(1): 6-11.
- [22] Wahyudi E (2015) Studi hubungan kuantitatif struktur aktivitas dari amidasi senyawa etil-p-metoksisinamat sebagai antiinflamasi dengan pendekatan Hansch dan komputasi. *Skripsi. UIN Syarif Hidayatullah Jakarta. Fakultas Kedokteran dan Ilmu Kesehatan*. <http://repository.uinjkt.ac.id/dspace/handle/123456789/29146>.
- [23] Pollastri MP (2010) Overview on the rule of five. *Current protocols in pharmacology* 49(1): 9-12.
- [24] Testa B, Carrupt PA, Gaillard P, Billois F, Weber P (1996) Lipophilicity in molecular modeling. *Pharm. Res.* 13: 335-343.
- [25] Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced drug delivery reviews* 23(1-3): 3-25.
- [26] Suhadi A, Rizarullah R, Feriyani F (2019) Simulasi docking senyawa aktif daun binahong sebagai inhibitor enzim aldose reductase. *Sel Jurnal Penelitian Kesehatan* 6(2): 55-65.
- [27] Barbezán AB, Martins R, Bueno JB, Villavicencio ALC (2017) Ames test to detect mutagenicity of 2-alkylcyclobutanones: A review. *Journal of Food Science* 82(7): 1518-1522.
- [28] Kesuma D, Purwanto BT, Hardjono S (2018) Uji in silico aktivitas sitotoksik dan toksisitas senyawa turunan N-(Benzoil)-N'-feniltiourea sebagai calon obat antikanker. *Journal of Pharmaceutical Science and Clinical Research* 3(1): 1-11.
- [29] Norma N, Latif UTA, Usman S (2014) Efek hepatotoksitas ekstrak etanol herba kompri (*Symphytum officinale* L.) terhadap hewan uji kelinci (*Oryctolagus cuniculus*) dengan parameter SGOT dan SGPT. *Biogenesis: Jurnal Ilmiah Biologi* 2(1): 11-15.
- [30] Khazanov NA, Carlson HA (2013) Exploring the composition of protein-ligand binding sites on a large scale. *PLoS Computational Biology* 9(11): e1003321.
- [31] Kilo AL (2018) *Kimia Anorganik Struktur dan Kereaktifan*. Gorontalo, UNG Press Gorontalo.